These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9761272)

  • 1. Effect of antiresorptive therapy on day-to-day variation of urinary free deoxypyridinoline excretion.
    Fradinger EE; Rodriguez G; Bogado C; Zanchetta JR
    Clin Chem; 1998 Oct; 44(10):2224-5. PubMed ID: 9761272
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
    Tucci JR; Tonino RP; Emkey RD; Peverly CA; Kher U; Santora AC
    Am J Med; 1996 Nov; 101(5):488-501. PubMed ID: 8948272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
    Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
    Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
    Asaba Y; Hiramatsu K; Matsui Y; Harada A; Nimura Y; Katagiri N; Kobayashi T; Takewaka T; Ito M; Niida S; Ikeda K
    Bone; 2006 Dec; 39(6):1276-82. PubMed ID: 16942925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
    Altundal H; Sayrak H; Yurtsever E; Göker K
    J Oral Maxillofac Surg; 2007 Mar; 65(3):508-16. PubMed ID: 17307600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimal osteoporosis strategy?].
    Scharla S; Reichenhall B
    Krankenpfl J; 2005; 43(1-3):65. PubMed ID: 15912853
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
    Ravn P; Alexandersen P; Møllgaard A
    Osteoporos Int; 1999; 9(4):277-83. PubMed ID: 10550443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
    Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.